Antiarrhythmic gene therapy: will biologics replace catheters, drugs and devices?
The clinical management of heart rhythm disorders still constitutes a major challenge. The development of alternatives to current approaches is of significant interest in order to establish more effective therapies that increase quality of life and reduce symptoms and hospitalizations. Over the past...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2 September 2016
|
| In: |
European journal of pharmacology
Year: 2016, Jahrgang: 791, Pages: 264-273 |
| ISSN: | 1879-0712 |
| DOI: | 10.1016/j.ejphar.2016.09.001 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.ejphar.2016.09.001 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S001429991630560X 
|
| Verfasserangaben: | Patrick Lugenbiel, Patrick A. Schweizer, Hugo A. Katus, Dierk Thomas |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1666633488 | ||
| 003 | DE-627 | ||
| 005 | 20230426220742.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190603s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejphar.2016.09.001 |2 doi | |
| 035 | |a (DE-627)1666633488 | ||
| 035 | |a (DE-599)KXP1666633488 | ||
| 035 | |a (OCoLC)1341225817 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Lugenbiel, Patrick |d 1982- |e VerfasserIn |0 (DE-588)137855710 |0 (DE-627)696120062 |0 (DE-576)305349414 |4 aut | |
| 245 | 1 | 0 | |a Antiarrhythmic gene therapy |b will biologics replace catheters, drugs and devices? |c Patrick Lugenbiel, Patrick A. Schweizer, Hugo A. Katus, Dierk Thomas |
| 264 | 1 | |c 2 September 2016 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 03.06.2019 | ||
| 520 | |a The clinical management of heart rhythm disorders still constitutes a major challenge. The development of alternatives to current approaches is of significant interest in order to establish more effective therapies that increase quality of life and reduce symptoms and hospitalizations. Over the past two decades the mechanistic understanding of pathophysiological pathways underlying cardiac arrhythmias has advanced profoundly, opening up novel avenues for mechanism-based therapeutic approaches. In particular, gene therapy offers greater selectivity than small molecule-based or interventional treatment. The gene of interest is packaged into viral or non-viral carriers and delivered to the target area via direct injection or using catheter-based techniques, providing the advantage of site-restricted action in contrast to systemic application of drugs. This work summarizes the current knowledge on mechanistic background, application strategies, and preclinical outcome of antiarrhythmic gene therapy for atrial fibrillation, ventricular tachycardia, and modulation of sinus node function. | ||
| 650 | 4 | |a Antiarrhythmic drug | |
| 650 | 4 | |a Atrial fibrillation | |
| 650 | 4 | |a Cardiac arrhythmia | |
| 650 | 4 | |a Gene therapy | |
| 650 | 4 | |a Sinus rhythm | |
| 700 | 1 | |a Schweizer, Patrick Alexander |d 1976- |e VerfasserIn |0 (DE-588)129886254 |0 (DE-627)48277987X |0 (DE-576)297887130 |4 aut | |
| 700 | 1 | |a Katus, Hugo |d 1951- |e VerfasserIn |0 (DE-588)108916618 |0 (DE-627)577155040 |0 (DE-576)289625076 |4 aut | |
| 700 | 1 | |a Thomas, Dierk |d 1974- |e VerfasserIn |0 (DE-588)123896258 |0 (DE-627)706465601 |0 (DE-576)29393164X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of pharmacology |d New York, NY [u.a.] : Elsevier, 1967 |g 791(2016), Seite 264-273 |h Online-Ressource |w (DE-627)300897340 |w (DE-600)1483526-5 |w (DE-576)081952627 |x 1879-0712 |7 nnas |a Antiarrhythmic gene therapy will biologics replace catheters, drugs and devices? |
| 773 | 1 | 8 | |g volume:791 |g year:2016 |g pages:264-273 |g extent:10 |a Antiarrhythmic gene therapy will biologics replace catheters, drugs and devices? |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejphar.2016.09.001 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S001429991630560X |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190603 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 123896258 |a Thomas, Dierk |m 123896258:Thomas, Dierk |d 910000 |d 910100 |e 910000PT123896258 |e 910100PT123896258 |k 0/910000/ |k 1/910000/910100/ |p 4 |y j | ||
| 998 | |g 108916618 |a Katus, Hugo |m 108916618:Katus, Hugo |d 910000 |d 910100 |e 910000PK108916618 |e 910100PK108916618 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 998 | |g 129886254 |a Schweizer, Patrick Alexander |m 129886254:Schweizer, Patrick Alexander |d 910000 |d 910100 |e 910000PS129886254 |e 910100PS129886254 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 137855710 |a Lugenbiel, Patrick |m 137855710:Lugenbiel, Patrick |d 910000 |d 910100 |e 910000PL137855710 |e 910100PL137855710 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1666633488 |e 3480822614 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"2 September 2016","dateIssuedKey":"2016"}],"language":["eng"],"relHost":[{"pubHistory":["1.1967 -"],"titleAlt":[{"title":"EJP"}],"id":{"zdb":["1483526-5"],"eki":["300897340"],"issn":["1879-0712"]},"title":[{"title_sort":"European journal of pharmacology","title":"European journal of pharmacology","subtitle":"EJP"}],"recId":"300897340","disp":"Antiarrhythmic gene therapy will biologics replace catheters, drugs and devices?European journal of pharmacology","part":{"pages":"264-273","year":"2016","extent":"10","volume":"791","text":"791(2016), Seite 264-273"},"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"origin":[{"publisherPlace":"New York, NY [u.a.]","dateIssuedKey":"1967","dateIssuedDisp":"1967-","publisher":"Elsevier"}],"type":{"media":"Online-Ressource","bibl":"periodical"}}],"person":[{"family":"Lugenbiel","roleDisplay":"VerfasserIn","given":"Patrick","display":"Lugenbiel, Patrick","role":"aut"},{"given":"Patrick Alexander","role":"aut","display":"Schweizer, Patrick Alexander","family":"Schweizer","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Katus","given":"Hugo","role":"aut","display":"Katus, Hugo"},{"roleDisplay":"VerfasserIn","family":"Thomas","display":"Thomas, Dierk","role":"aut","given":"Dierk"}],"name":{"displayForm":["Patrick Lugenbiel, Patrick A. Schweizer, Hugo A. Katus, Dierk Thomas"]},"physDesc":[{"extent":"10 S."}],"note":["Gesehen am 03.06.2019"],"recId":"1666633488","title":[{"title_sort":"Antiarrhythmic gene therapy","title":"Antiarrhythmic gene therapy","subtitle":"will biologics replace catheters, drugs and devices?"}],"id":{"eki":["1666633488"],"doi":["10.1016/j.ejphar.2016.09.001"]}} | ||
| SRT | |a LUGENBIELPANTIARRHYT2201 | ||